Your Messages Inbox
Your Article Summary
See Latest ArticlesFDA Approves EMBEDA for Management of Moderate to Severe Chronic Pain
King Pharmaceuticals, 08/14/09
King Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved EMBEDA Extended Release Capsules for oral use, a long–acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around–the–clock opioid analgesic is needed for an extended period of time. EMBEDA is the first FDA–approved long–acting opioid that is designed to reduce drug liking and euphoria when tampered with by crushing or chewing.
Related Articles
Chronic pain alters the structure of the brain
Schmerz, 10/20/09
Relevance Score: 72%
Acute postoperative pain as a risk factor for chronic pain after surgery
European Journal of Pain, 11/12/09
Relevance Score: 71%
Brain Gray Matter Decrease in Chronic Pain Is the Consequence and Not the Cause of Pain
Journal of Neuroscience, 11/10/09
Relevance Score: 71%
Chronic pain-related changes in endogenous opioid analgesia: A case report
Pain, 10/16/09
Relevance Score: 71%
Prognosis for patients with chronic low back pain: inception cohort study
British Medical Journal, 10/09/09
Relevance Score: 71%
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Article Search
Sponsor